DEFA14A: Adaptive Biotechnologies Defends Directors Amid ISS Overboarding Concerns

Adaptive Biotechnologies urges stockholders to re-elect directors Peter Neupert and Michelle Griffin, addressing concerns raised by ISS regarding Dr. Rob Hershberg's board memberships.

Summary

• Adaptive Biotechnologies is addressing concerns raised by Institutional Shareholder Services (ISS) regarding the re-election of directors Peter Neupert and Michelle Griffin at the 2024 Annual Meeting of Stockholders.
• ISS recommends withholding votes for Neupert and Griffin due to concerns that Dr. Rob Hershberg, a co-director, is 'overboarded' by serving on more than three public boards while being a CEO.
• Adaptive Biotechnologies strongly disagrees with ISS's recommendation and provides supplemental information to support the re-election of Neupert and Griffin.
• Dr. Hershberg will no longer be a member of the Board of Directors of Fate Therapeutics as of June 7, 2024.
• After June 7, 2024, Dr. Hershberg will serve on the Boards of Recursion Pharmaceuticals, Inc. and HilleVax, Inc., in addition to Adaptive Biotechnologies.
• The company states that Dr. Hershberg attended all shareholder engagement meetings and every Board and Compensation Committee meeting in 2023.
• Adaptive Biotechnologies emphasizes that Dr. Hershberg's board memberships meet the requirements of the company's bylaws, which allow service on up to five public company boards.
• The Board believes that Dr. Hershberg's service on other boards does not impair his ability to serve Adaptive Biotechnologies effectively.
• Adaptive Biotechnologies urges stockholders to vote for all director nominees and the say-on-pay proposal.

Sentiment

Score: 6

Explanation: The document is defensive, addressing concerns raised by ISS. While the company presents a case for its directors, the need to respond to negative recommendations suggests underlying governance challenges.

Positives

• Dr. Hershberg is stepping down from the board of Fate Therapeutics, reducing his board commitments.
• Dr. Hershberg actively participates in board and committee meetings.
• Dr. Hershberg's board memberships are within the limits set by the company's bylaws.

Negatives

• ISS has recommended withholding votes for two directors due to concerns about a co-director's board memberships.
• The company has to spend time and resources to defend its directors against ISS's recommendation.

Risks

• Negative vote recommendations from proxy advisory firms like ISS could influence shareholder voting decisions.
• Continued concerns about director overboarding could lead to further scrutiny from investors and proxy advisors.

Future Outlook

Adaptive Biotechnologies aims to deliver sustainable stockholder value through continued engagement and effective corporate governance.

Management Comments

• We strongly and respectfully disagree with ISS's recommendation.
• The Board submits that Dr. Hershberg's service on the Boards of two other companies does not in any way impair his ability to be of full service to the Company's Board.
• We appreciate the opportunity to communicate with stockholders and look forward to continued engagement as we work to deliver sustainable stockholder value.

Industry Context

Proxy advisory firms like ISS play a significant role in influencing shareholder voting decisions, particularly on matters of corporate governance. Companies often respond to ISS recommendations to address concerns and ensure support for management proposals.

Comparison to Industry Standards

• Director overboarding is a common concern raised by proxy advisory firms.
• ISS and Glass Lewis often have specific guidelines on the number of boards a director can serve on, particularly for CEOs.
• Companies like Fate Therapeutics, Recursion Pharmaceuticals, and HilleVax are peers in the biotechnology and pharmaceutical industries, and their corporate governance practices are often compared.

Stakeholder Impact

• Shareholders are urged to vote for the re-election of directors.
• The outcome of the vote could impact the composition and effectiveness of the Board of Directors.
• Employees and other stakeholders could be affected by changes in the company's leadership and governance.

Next Steps

• Stockholders will vote on the re-election of directors at the 2024 Annual Meeting on June 7, 2024.
• Adaptive Biotechnologies hopes ISS will reconsider its recommendation based on the additional information provided.

Key Dates

Keywords

Adaptive Biotechnologies, Board of Directors, ISS, Proxy Statement, Director Re-election, Overboarding, Shareholder Vote, Corporate Governance